ICMR completes trials for world's first injectable male contraceptive, data shows it's safe and effective

In a major breakthrough in the field of contraceptive and birth control, the Indian Council of Medical Research (ICMR) completed the clinical trials of the world's first injectable male contraceptive. The clinical trial showed that the method is safe and highly efficacious without any serious side effects.The phase-3 of the clinical trial, involved 303 candidates aged 25-40 years. The findings of the ICMR clinical trials were published in the international open access Andrology journal last month.The clinical trial were carried out at five different locations in the country. The centres for trials were located in New Delhi, Udhampur, Ludhiana, Jaipur and Kharagpur) and coordinated by the ICMR, New Delhi.

The open-labelled and non-randomized, multi-centre hospital-based phase-III clinical trials were carried out after getting permission from the Drugs Controller General India (DCGI). It was approved by the institutional ethical committees of the respective centres.About the ICMR study on injectable male contraceptives

Under the study, a total of 303 healthy, sexually active and married men and their healthy and sexually active wives were included. These couples were selected for the trials after they came to the family planning clinic and department of urology or surgery for vasectomy or No Scalpel Vasectomy (NSV) were identified. 

During the trials, men were injected with 60 mg of Reversible Inhibition of Sperm under Guidance (RISUG).

According to the study, the huge surge in world population, led to an urgent need to develop modern methods of male contraception for population control.Study finding

The ICMR trials indicated that the RISUG method presented the highest effectiveness compared to all other contraceptives for both males and females.

"The overall efficacy of RISUG with respect to achieving azoospermia was 97.3 per cent and based on pregnancy prevention was 99.02 per cent without any serious side effect," the study stated."In the history of contraceptive development, RISUG presents the highest effectiveness compared to all other contraceptives both male and female as they were at the threshold of induction into a mass contraception program," it said.

However, vasectomy is considered quite effective as a contraceptive measure.

"To achieve these goals, a novel male contraceptive approach of Reversible Inhibition of Sperm under Guidance (RISUG) has been developed, which has the potential to become for mass use as once injectable and reversible male contraceptive method. Significant features of this method include localized injection and no detectable interaction with other body parts unlike the hormonal injectable contraceptives," the study said

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!